Boston Scientific stock trades at EUR 40.89 ahead of October 28 results
Published on 10/26/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming results test the setup
- Boston Scientific scheduled third-quarter results before the market opens on October 28, 2026.
- Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year.
- Boston Scientific stock trades at EUR 40.89 at 10:29 a.m. CET at Lang & Schwarz on October 26, 2026, 0.70 percent above the Xetra close of October 23, 2026.
Boston Scientific stock was trading at EUR 40.89 at Lang & Schwarz on October 26, 2026, at 10:29 a.m. CET, up 0.70 percent versus the Xetra close of October 23, 2026, at EUR 40.61. The immediate test is the company's third-quarter report scheduled before the market opens on October 28, 2026, according to MarketBeat.
Earnings date sets near-term test
The scheduled report follows a second quarter in which Boston Scientific generated USD 5.44 billion in revenue, an increase of 7.50 percent from the prior-year quarter. Adjusted earnings per share reached USD 0.86 against a USD 0.83 consensus, while revenue exceeded the USD 5.38 billion estimate, according to MarketBeat.
For the third quarter, the company set adjusted earnings guidance of USD 0.80 to USD 0.82 per share. Analysts cited by MarketBeat expect USD 0.746 per share and USD 5.10 billion in revenue, putting the report's guidance range above the published earnings estimate.
What does the target imply?
Analyst expectations remain wide. MarketBeat reported a USD 68.23 average 12-month target from 31 analysts on October 25, 2026, while its survey also listed recent reductions by several brokerages. Leerink Partners cut its target from USD 60.00 to USD 55.00 in a note dated October 9, 2026, as reported by MarketBeat. The contrast is useful for investors: the earnings beat was measurable, but target revisions show that confidence in the full-year path is less uniform.
Three dated company markers
On July 29, 2026, Boston Scientific reported USD 5.44 billion in second-quarter revenue and adjusted earnings per share of USD 0.86, according to Boston Scientific. On October 7, 2026, it appointed Joseph M. Fitzgerald executive vice president and chief operating officer, effective January 1, 2027. On October 28, 2026, the company is scheduled to report third-quarter results before the market opens.
Dates for the earnings calendar
The next confirmed company date is October 28, 2026, for the third-quarter report before the market opens. The conference call is scheduled for 8:00 a.m. ET on the same date, according to Boston Scientific.
Stock holds above the Xetra close
The euro quotation is modestly above the Xetra reference level, while the upcoming report supplies the next dated catalyst. Boston Scientific was trading at EUR 40.89 at Lang & Schwarz on October 26, 2026, at 10:29 a.m. CET, 0.70 percent above the Xetra close of October 23, 2026, at EUR 40.61. The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- WKN: 884113
- Ticker: BSX
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 26, 2026, 10:29 a.m. CET): EUR 40.89
- Change versus Xetra close: plus 0.70 percent
- Xetra close (October 23, 2026): EUR 40.61
- Market capitalization: USD 66.2 billion (as of October 23, 2026)
- 52-week range: USD 41.39-105.65 (as of October 23, 2026)
- Sector / Industry: Healthcare / Medical devices
Market context: Market report S&P 500.
